Syndax Pharmaceuticals Ownership

SNDX Stock

USD 10.28 0.55 5.65%

The majority of Syndax Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Syndax Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Syndax Pharmaceuticals. Please pay attention to any change in the institutional holdings of Syndax Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.

Shares in Circulation

First Issued

2012-12-31

Previous Quarter

85.8 M

Current Value

85.6 M

Avarage Shares Outstanding

46.1 M

Quarterly Volatility

29.6 M

Yuan Drop

Covid

Some institutional investors establish a significant position in stocks such as Syndax Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Syndax Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Market Cap Enterprise Value

Build AI portfolio with Syndax Stock

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Syndax Stock Ownership Analysis

About 99.0% of the company shares are owned by institutional investors. The book value of Syndax Pharmaceuticals was at this time reported as 2.5. The company has Price/Earnings (P/E) ratio of 126.11. Syndax Pharmaceuticals recorded a loss per share of 3.85. The entity had not issued any dividends in recent years. Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts. Syndax Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people. To find out more about Syndax Pharmaceuticals contact Michael MBA at 781 419 1400 or learn more at https://syndax.com.

Syndax Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Syndax Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syndax Pharmaceuticals backward and forwards among themselves. Syndax Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Syndax Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Franklin Resources Inc	2025-03-31	2.1 M
Assenagon Asset Management Sa	2025-06-30	2 M
Geode Capital Management, Llc	2025-03-31	2 M
Kingdon Capital Management Llc	2025-03-31	2 M
Woodline Partners Lp	2025-03-31	1.9 M
Balyasny Asset Management Llc	2025-03-31	1.8 M
Catalio Capital Management, Lp	2025-03-31	1.7 M
Ubs Group Ag	2025-03-31	1.7 M
Sphera Funds Management Ltd.	2025-03-31	1.7 M
Blackrock Inc	2025-03-31	8.5 M
Kynam Capital Management, Lp	2025-03-31	8.5 M

Note, although Syndax Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Syndax Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syndax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syndax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syndax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Metzger Michael A few days ago Disposition of 7534 shares by Metzger Michael A of Syndax Pharmaceuticals at 9.285 subject to Rule 16b-3
		Botwood Nicholas A.j. over two months ago Acquisition by Botwood Nicholas A.j. of 11765 shares of Syndax Pharmaceuticals at 8.995 subject to Rule 16b-3
		Goldan Keith A. over three months ago Acquisition by Goldan Keith A. of 23400 shares of Syndax Pharmaceuticals subject to Rule 16b-3
		Metzger Michael A over three months ago Acquisition by Metzger Michael A of 6074 shares of Syndax Pharmaceuticals at 7.2 subject to Rule 16b-3
		Ordentlich Peter over three months ago Disposition of 17428 shares by Ordentlich Peter of Syndax Pharmaceuticals at 25.8437 subject to Rule 16b-3
		Gallagher Neil over six months ago Acquisition by Gallagher Neil of 69375 shares of Syndax Pharmaceuticals at 22.28 subject to Rule 16b-3
		Jarrett Jennifer over a year ago Acquisition by Jarrett Jennifer of 17000 shares of Syndax Pharmaceuticals subject to Rule 16b-3
		Peter Ordentlich over a year ago Acquisition by Peter Ordentlich of 90000 shares of Syndax Pharmaceuticals at 28.55 subject to Rule 16b-3
		Briggs Morrison over a year ago Acquisition by Briggs Morrison of 52855 shares of Syndax Pharmaceuticals at 8.77 subject to Rule 16b-3
		Dennis Podlesak over a year ago Acquisition by Dennis Podlesak of 34000 shares of Syndax Pharmaceuticals subject to Rule 16b-3
		Peter Ordentlich over a year ago Exercise or conversion by Peter Ordentlich of 7572 shares of Syndax Pharmaceuticals subject to Rule 16b-3

Syndax Pharmaceuticals Outstanding Bonds

Syndax Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Syndax Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Syndax bonds can be classified according to their maturity, which is the date when Syndax Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	SNV 5625 15 FEB 28 Corp Bond US87164DVJ61	View
	SYNCHRONY FINL 45 Corp Bond US87165BAG86	View
	SYNCHRONY FINL 395 Corp Bond US87165BAM54	View
	SYNCHRONY FINL 37 Corp Bond US87165BAL71	View
	SYF 2875 28 OCT 31 Corp Bond US87165BAR42	View
	SYF 725 02 FEB 33 Corp Bond US87165BAU70	View
	SNX 265 09 AUG 31 Corp Bond US87162WAK62	View
	SNX 175 09 AUG 26 Corp Bond US87162WAF77	View

View All Syndax Pharmaceuticals Corporate Bonds

Syndax Pharmaceuticals Corporate Filings

F4	18th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
8K	26th of June 2025 Report filed with the SEC to announce major events that shareholders should know about	View Verify
	9th of May 2025 Other Reports	View Verify
	1st of April 2025 Other Reports	View Verify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GOOG	Alphabet Inc Class C
V	Visa Class A

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC